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Summary EDAcFN enzyme immunoassay (EIA) is a new tumour marker assay measuring the extra domain A-containing isoform of cellular
fibronectin (cFN), a component mainly found in extracellular matrices. The concentration cFN was measured in plasma and serum from 468
patients with malignant and benign diseases. The concentrations of cFN were higher in plasma than in serum. Using receiver operating
characteristic (ROC) curve analysis, determination from plasma was superior to serum at specificity levels higher than 78% and was chosen
for further analysis. The highest frequencies of elevated cFN values were seen in patients with hepato-pancreato-biliary malignancies
(50-67%). In pancreatic and bile duct cancers, cFN provided little further information to that obtained by CA 19-9. The greatest advantage
over CA 19-9 and CEA was seen in patients with local colorectal cancer and in hepatocellular carcinomas. Four out of nine patients with
Dukes' stage B colorectal cancer had an elevated cFn level, but only one had an abnormal CEA level. In hepatocellular carcinomas, cFN was
also compared with alpha-fetoprotein. The sensitivity of cFN (72%) was superior to that of AFP (61%), and concomitant use of cFN and AFP
raised the sensitivity to 83%. The highest frequencies of elevated values in patients with benign diseases were observed in those with severe
liver disease (32%) and biliary (17%) and pancreatic (24%) diseases. A combination of cFN and CA 19-9 showed the highest overall
sensitivity of 47%, compared with 31% for cFN and 33% for CA 19-9. The corresponding specificities were 76% for cFN ± CA 19-9, 85% for
cFN and 83% for CA 19-9. The accuracy of a combination of cFN and CA 19-9 or CEA (60% respectively) was higher than that of cFN (55%),
CA 19-9 (55%) or CEA (45%) alone. In conclusion, the results of the new cFN test are encouraging and further studies on larger patient
materials have been started.
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Fibronectins (FN) are adhesive glycoproteins that have variable
primary structures owing to cell type-specific splicing of FN
precursor mRNA. FNs can be divided into two majorforms: plasma
fibronectin (pFN), a soluble component ofplasma and body fluids,
and cellular fibronectin (cFN), mainly found in extracellular
matrices. cFNs differfrompFN inhaving the so-called extradomain
(ED) sequences A or B in the molecule (Schwarzbauer, 1991).
Plasma FN is produced by hepatocytes, while cFNs are produced
locally (Tamkun et al, 1983). However, plasma also contains small
quantities ofcFN (Vartio et al, 1987; Ylatupa et al, 1995a,b).
FNs have a role in various biological phenomena, such as tissue
organization, cell adhesion, mobility and differentiation, as well as
in tumour invasion and metastasis (Yamada et al, 1985; Humphries
et al, 1988; Coachman et al, 1990; Schwarzbauer, 1991). In many
studies, total FN in plasma and other body fluids has been evalu-
ated as a marker for cancer or other diseases (Parsons et al,
1979a,b; Webb and Linn, 1980; Stathakis et al, 1981; Choate and
Mosher, 1983; Siri et al, 1984; Boccardo et al, 1986; Ruelland et al,
1988; Katayama et al, 1991). Only recently have specific anti-
bodies made it possible to study the cellular form ofFN containing
the EDA sequence (EDAcFN). In immunohistochemical stainings,
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EDAcFN has been shown to be present in abundance in certain
developing basement membranes and in reactive adult tissues
(Vartio et al, 1987; Virtanen et al, 1988; Gould et al, 1990, 1992;
Laitinen et al, 1991; Glukhova and Thiery, 1993; Koukoulis et al,
1993). EDAcFN also showed a strong expression in the stroma
of all carcinomas studied by Vartio et al (1987). A quantitative
enzyme immunoassay based on the monoclonal antibody (MAb)
DHI detecting the EDAcFN has been described (Ylatupa et al,
1993, 1995a). In a recent report, cFN in plasma and serum was
shown to be a promising tumour marker (Ylatupa et al, 1995b). In
this study, data from patients with various malignant and benign
diseases are reported. The results ofcFN are compared with those
ofCA 19-9 and CEA, two widely used markers in clinical practice.
MATERIALS AND METHODS
Serum and plasma samples
Serum samples were obtained from 261 patients with different
malignancies and from 207 patients with various benign diseases.
Blood was collected by venepuncture into sodium EDTA (final
concentration 4 mmol 1-'). Plasma was separated by centrifugation
at 1400g at room temperature. Blood for serum samples was
allowed to coagulate at +4°C for 1 h before separation by centrifu-
gation. Samples were stored at-70°C and thawed at +4'C for 12 h
before the assay. In patients with recurrent colorectal carcinoma,
the samples were taken at the time of clinical verification. In all
other cancer patients, the samples were taken before surgical
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Table 1 Cellular fibronectin (cFN) in plasma and CA 19-9 and CEA in serum in 261 patients with various malignant diseases
Diagnosis (malignancy) n p-cFN > 6.5 mg 1-' CA 19-9 > 35 U ml-' CEA > 5 ng ml-'
%(n) %(n) %(n)
Oesophageal
Gastric
Stage
Stage II
Stage IlIl
Stage IV
Small bowel
Colorectal
Dukes stage B
Dukes stage C
Dukes stage D
Recurrent disease
Liver (hepatocellular)
Stage IlIl
Stage IV
Liver (bile duct)
Stage IlIl
Stage IV
Biliary (extrahepatic)
Stage II
Stage IlIl
Stage IV
Ampulla of Vater
Pancreatic
Stage
Stage II
Stage IlIl
Stage IV
Breast
Stage 0 (in situ)
Stage
Stage II
Stage IlIl
Sarcoma
Lung
Urological
Melanoma
Thyroid
Lymphoma
Total
therapy. Patients receiving chemotherapy orradiotherapy were not
included in the study. The diagnoses were based on histological or
cytological data and on clinical and laboratory findings. Patients
with malignant tumours were divided into three groups: 144
patients with digestive tract malignancy (four oesophageal, 18
gastric, three small bowel, 35 colorectal, 33 pancreatic, 21 liver,
seven intrahepatic biliary, 20 extrahepatic biliary and three
ampulla of Vater), 79 patients with breast cancer and 38 patients
with miscellaneous malignancies (two urinary bladder, six renal,
two prostatic, nine lung, one thyroid, ten sarcomas, six lymphomas
and one eye melanoma) (Table 1).
The group of benign diseases comprised. 180 patients with
benign digestive tract diseases (four oesophageal, eight gastric,
23 small bowel, 15 colorectal, 22 liver, 59 biliary, one ampulla of
Vater, 38 pancreatic and ten patients with abdominal pains of
unknown origin), 22 with benign breast diseases, one benign lung
and four with renal insufficiency (Table 2).
Cancer patients were classified according to the UICC TNM
classification, except for patients with colorectal cancer for whom
the modified Dukes' classification was used (Turnball et al, 1967).
This study was carried out with ethical committee approval.
Assays
The concentration of EDAcFN in serum and plasma samples was
measured using an enzyme immunoassay as described previously
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18
2
6
2
8
3
35
9
5
6
14
21
8
13
7
2
5
20
2
5
13
3
3,3
2
11
10
10
79
3
33
36
7
10
9
10
2
6
261
50 (2)
17 (3)
(1)
(0)
(0)
(2)
0 (0)
20 (7)
(4)
(0)
(1)
(2)
67 (14)
(4)
(10)
57 (4)
(1)
(3)
50 (10)
(2)
(1)
(7)
67 (2)
55 (18)
(0)
(8)
(4)
(6)
18 (14)
(0)
(8)
(5)
(1)
20 (2)
11 (1)
40 (4)
50 (1)
0 (0)
0 (0)
82
0 (0)
44 (8)
(0)
(1)
(1)
(6)
33 (1)
37 (13)
(0)
(2)
(4)
(7)
43 (9)
(2)
(7)
100 (7)
(2)
(5)
85 (17)
(2)
(4)
(11)
67 (2)
79 (26)
(0)
(9)
(7)
(10)
3 (2)
(0)
(1)
(1)
(0)
10 (1)
0 (0)
10 (1)
0 (0)
0 (0)
0 (0)
87
0 (0)
22 (4)
(0)
(0)
(1)
(3)
33 (1)
49 (17)
(1)
(2)
(5)
(9)
14 (3)
(0)
(3)
43 (3)
(1)
(2)
15 (3)
(0)
(0)
(3)
0 (0)
30 (10)
(0)
(2)
(2)
(6)
1 (1)
(0)
(0)
(1)
(0)
0 (0)
33 (3)
0 (0)
0 (0)
0 (0)
0 (0)
45
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Table 2 Cellular fibronectin (cFN) in plasma and CA 19-9 and CEA in serum in 207 patients with various benign diseases
Diagnosis (benign disease) n p-cFN > 6.5 mg 1-' CA 19-9 > 35 U ml-1 CEA > 5 ng ml-'
% (n) % (n) % (n)
Oesophageal 4 0 (0) 0 (0) 0 (0)
Gastric 8 13 (1) 13 (1) 13 (1)
Small bowel 23 9 (2) 0 (0) 9 (2)
Colorectal 15 7 (1) 0 (0) 0 (0)
Liver 22 32 (7) 41 (9) 14 (3)
Biliary 59 17 (10) 25 (15) 0 (0)
AmpullaofVater 1 0 (0) 0 (0) 0 (0)
Pancreatic 38 24 (9) 21 (8) 5 (2)
Abdominal pains 10 0 (0) 10 (1) 0 (0)
Breast 22 0 (0) 0 (0) 0 (0)
Lung 1 0 (0) 0 (0) 0 (0)
Kidney 4 25 (1) 25 (1) 0 (0)
Total 207 31 35 8
C
0
0
9- 0.4-
0.2- 0 a)
0. , .a
0 0.2 0.4 0.6 0.8 1.0
False-positive fraction
Figure 1 A comparison of EDAcFN in serum (-) and plasma --- - -) from
261 patients with various malignant diseases using receiver operating curve
(ROC) analysis. The control group comprises 207 patients with benign
diseases
(Ylatupa et al, 1995a). In short, microtitration strips coated with
MAb DHl against EDAcFN were washed. Thereafter, 100 pl of
sample or standard was added and incubated for 1 h at +37°C. The
unbound material was removed by washing and 100g1 of peroxi-
dase-conjugated BE2 antibody was added. After incubation at
+37'C for 1 h, the strips were washed and the substrate incubation
was allowed to proceed for 30 min. After stopping the reaction,
absorbance was measured at 450 nm. The coefficient of variation
(CV) for measurement ofboth interassay and intra-assay standards
(n = 12) and samples (n = 2) was less than 10%. The intra-assay
CV varied between 1.7% and 7.7% and the interassay CV ranged
between 2.7% and 9.0%. The detection limit of the assay was
0.05 mg 1-'. Cut-off values of 6.5 mg l-1 and 1.1 mg 1-', repre-
senting the 97.5th percentiles of healthy blood donors, were used
for plasma cFN and serum cFN respectively.
Serum CA 19-9 and CEA levels were measured on the
Technicon Immuno 1 system (Bayer, Tarrytown, NY, USA). Cut-
offvalues of35 U ml-' and 5 ng mr', respectively, were used.
The results of the following laboratory tests were collected
from clinical records of the patients: aspartate aminotransferase
(ASAT), alanine aminotransferase (ALAT), y-glutamyl transferase
(y-GT), alkaline phosphatase, bilirubin, amylase, creatinine,
albumin, C-reactive protein (CRP), thromboplastin time (TT-
SPA), activated partial thromboplastin time (APTT) and alpha
fetoprotein (AFP).
Statistical methods
Thecorrelation betweenthe concentrations ofdifferent markers was
calculated using the Spearman rank correlation test. Differences in
mean values were calculated using the Mann-Whitney U-test for
non-paired samples. Receiver operating characteristic (ROC)
curves were constructed by calculating the true-positive fraction
(sensitivities) and false-positive fraction (specificities) of the
markers at several cut-offpoints (Metz et al, 1978).
RESULTS
Comparison of plasma and serum levels of EDAcFN
In all patients both plasma and serum levels of cFN were
measured. When comparing the two methods by ROC curve
analysis, determination from plasma was superior to serum at
specificity levels higher than 78% (Figure 1). The correlation
between the cFN concentration in plasma and serum was low
(rs = 0.323). For further analysis and comparison with other
markers, the plasma levels ofcFN were chosen.
EDAcFN in plasma of patients with benign diseases
In 207 patients with benign diseases the mean plasma concentra-
tion of EDAcFN was 4.39 mg 1-1 (range 0-25.03 mg 1-') and the
median concentration was 3.21 mg 1-'.
The plasma cFN level was elevated in 15% (31 out of 207) of
patients with benign disease, in 17% (30 out of 180) of patients
with digestive tract disease, in none of the patients with benign
breast disease and in one out of five patients with other benign
disease (Table 2). The highest frequencies ofelevated values were
seen in patients with benign liver (32%), biliary (17%) and pancre-
atic (24%) diseases. Five out of seven patients with liver disease
and elevated cFN had alcoholic cirrhosis, one had acute hepatitis
and one benign liver disease of unknown aetiology. Elevated cFN
was seen in five patients with benign biliary disease with signs of
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Figure 2 A comparison of plasma EDAcFN (--- - -), serum CA 19-9 (-)
and serum CEA (- -) in 261 patients with various malignant diseases using
receiver operating curve (ROC) analysis. The control group comprises 207
patients with benign diseases
bile duct obstruction and five without obstruction. Plasma cFN
was elevated in 9 out of 38 patients with benign pancreatic
diseases, in three patients with chronic and six with acute pancre-
atitis, five of whom had alcoholic and one biliary pancreatitis.
EDAcFN in plasma of carcinoma patients
In 261 patients with malignant diseases the mean plasma concen-
tration of EDAcFN was 6.05 mg 1-' (range 0-27.43 mg 11') and the
median concentration was 4.27 mg 11'. The EDAcFN concentra-
tion was significantly higher in malignant than in benign diseases
(P = 0.003)-
An elevated plasma cFN level was found in 31% (82 patients)
of 261 patients with malignant disease, in 42% (60 out of 144) of
those with digestive tract cancer, in 18% (14 out of79) with breast
cancer and in 21% (8 out of 38) in the miscellaneous group. The
frequencies of elevated plasma EDAcFN concentrations in the
various subgroups studied are shown in Table 1. The highest
frequency of elevated values was seen in patients with hepato-
pancreato-biliary tumours. Sixty-seven per cent of patients with
liver tumours (14 out of21) had an elevated cFN level. This group
consisted mainly of hepatocellular carcinomas. The plasma cFN
concentration was increased in four out of seven (57%) intrahep-
atic cholangiocarcinomas, in 10 out of 20 extrahepatic cholangio-
carcinomas (50%), in two out of three (67%) carcinomas of the
ampulla ofVater and in 18 out of33 pancreatic carcinomas (55%).
There was no correlation between the plasma cFN concentra-
tions and the serum concentration of ASAT, ALAT, GT, alkaline
phosphatase, bilirubin, amylase, creatinine, albumin, C-reactive
protein, TT-SPA or APTT (rs = 0.043-0.363).
Comparison of cFN, CA 19-9 and CEA
There was no correlation between the plasma levels of cFN and
serum concentrations of CA 19-9 (rs = 0.386) and CEA (rs =
0.249). ROC curve analysis demonstrates the difference in sensi-
tivities of cFN, CA 19-9 and CEA at various specificity levels
(Figure 2).
Combination of cFN with CA 19-9, requiring either or both
markers to be elevated for a positive test result, increased the
sensitivity to 47% compared with 31% for cFN alone and 33% for
CA 19-9. The specificity decreased to 76% for the combination,
compared with 85% and 83% for cFN and CA 19-9 respectively.
The corresponding sensitivities for digestive tract malignancies
were 69%, 42% and 58% respectively; and the specificities, based
on benign digestive tract diseases, were 73%, 83% and 81%
respectively (Table 3).
Table 3 Assay parameters for cellular fibronectin (cFN), CA 19-9 and CEA and their combinations in 261 patients with malignant and 207 with benign diseases
n p-cFN+a (%) CA 19-9+ (%) CEA+(%) p-cFN+ and/or p-cFN+ and/or CA 19-9+and/or
CA 19-9+ (%) CEA+ (%) CEA+(%)
Overall
Sensitivity 261 31 33 17 47 41 36
Specificity 207 85 83 96 76 83 81
Accuracy 55 55 43 60 60 56
Digestive tract diseases
Sensitivity 144 42 58 28 69 57 60
Specificity 180 83 81 96 73 81 78
Accuracy 65 71 66 71 70 70
Breast cancer
Sensitivity 79 18 3 1 20 19 4
Specificity 22 100 100 100 100 100 100
Accuracy 36 24 1 38 37 25
Miscellaneous malignancies
Sensitivity 38 21 5 8 21 29 13
Specificity 5 80 80 100 80 80 80
Accuracy 28 14 19 28 35 21
a+, higher than the cut-off value of 6.5 mg 1-', 35 U ml-1 and 5 ng ml- for cFN, CA 19-9 and CEA respectively. Sensivity = TP/(TP+FN); specificity = TN/(TN+FP);
accuracy = (TP+TN)/(TP+FN+TN+FP) TP, true positive; FN, false negative; TN, true negative; FP, false positive.
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The sensitivity of cFN plus CEA was 41% compared with 31%
for cFN alone and 17% for CEA alone. The specificity decreased
to 83% for the combination, compared with 85% and 96% for cFN
alone and CEA alone respectively. The corresponding sensitivities
for digestive tract malignancies were 57%, 42% and 28% respec-
tively; and the specificities, based on benign digestive tract
diseases, were 81%, 83% and 96% respectively (Table 3).
The accuracy, i.e. the percentage of correct test results (negative
for benign and positive for malignant) out of all tested patients,
was 60% for cFN plus CA 19-9, 60% for cFN plus CEA,
compared with 55% for cFN alone, 55% for CA 19-9 and 43% for
CEA. The corresponding figures for digestive tract malignancies
were 71%, 70%, 65%, 71% and 66% respectively (Table 3).
Serum AFP was not determined in our patients, but in 18
patients the AFP levels were available from clinical records. The
sensitivity of AFP (> 10 U 1-1) was 61% compared with 72% for
cFN. Four AFP-negative patients had an elevated cFN level. A
combination of both markers increased the sensitivity to 83% (15
out of 18 patients).
DISCUSSION
Fibronectins (FNs) play a role in tumour invasion and metastasis
(Humphries et al, 1988; Schwarzbauer, 1991). Accordingly, assays
measuring the circulating levels of FN are potential tumour
markers for different malignancies. Elevated plasma levels oftotal
FN have been reported in patients with solid tumours, such as
pancreatic, colon, lung, ovarian and breast carcinomas (Mosher
and Williams, 1978; Parsons et al, 1979a,b; Todd et al, 1980;
Choate and Mosher, 1983), whereas normal FN concentrations
have been reported in patients with leukaemia (Bruhn and
Heimburger, 1976; Choate and Mosher, 1983). On the other hand,
Eijan et al (1986) did not find elevated total FN levels in breast
cancer, and increased plasma concentrations of total FN levels
may also be found in various benign conditions (Todd et al, 1980).
It is obvious that the clinical usefulness of total plasma FN as a
tumour marker is limited and, recently, interest has been focused
on the expression of different fragments or isoforms of FN. FN
fragments in urine have been studied as a marker for malignancy
(Katayama et al, 1991), and different isoforms of FN, including
EDAcFN and oncofetal FN, have been studied as markers for
benign conditions, such as vascular injury and acute pulmonary
injury, or as a predictor of pre-term delivery (Peters et al, 1988,
1989; Lockwood et al, 1991).
We previously described an EIA detecting low concentrations of
EDAcFN in both plasma and serum ofhealthy individuals (Ylatupa
et al, 1993, 1995a). A preliminary evaluation of 120 patients with
various malignancies indicated that this new assay might be useful
as a tumour marker test (Ylatupa et al, 1995b). For this study, data
from 261 patients with different malignancies and 207 patients
with various benign diseases were collected. In all the patients, the
cFN concentration was measured both in serum and in plasma. In
addition, the levels of the commonly used tumour markers CA 19-
9 and CEA were measured from the same serum samples. The
concentration of cFN in serum was clearly lower than that in
plasma, which is apparently due to binding of FN to fibrin in blood
clotting (Engvall et al, 1978; Ylatupa et al, 1993). EDTA was used
as the coagulant to obtain plasma. Heparin has been shown to bind
to FN, thereby causing it to precipitate (Stathakis and Mosesson,
1977). Citrated plasma did not give good reproducibility in our
method (Ylatupa et al, 1993). Using ROC analysis, EDAcFN in
plasma showed a higher sensitivity than EDAcFN in serum at
specificity levels higher than 78% (Figure 1). There was a surpris-
ingly low correlation between the levels in plasma and those in
serum. It seems that the amount of FN lost in blood clotting is
unpredictable, as has also been shown by Boccardo et al (1986).
For further analysis and comparison with other markers, we
decided to use only the plasma concentrations of EDAcFN.
The cellular form of FN is mainly found in extracellular
matrices and, immunohistochemically, a strong expression of
EDAcFN has been shown in various malignant tumours (Vartio et
al, 1987; Gould et al, 1990; Koukoulis et al, 1993; Famoud et al,
1995; Lohi et al, 1995; Natali et al, 1995). In patients with malig-
nant diseases, the circulating levels of cFN were clearly increased
compared with the plasma levels of healthy individuals. Plasma
cFN was more often elevated in digestive tract malignancies
(42%) than in breast cancer (18%) or in the group ofmiscellaneous
tumours (21%). The highest frequency ofelevated values was seen
in patients with hepato-pancreato-biliary cancers (50-67%), i.e.
the same cancer forms that frequently express CA 19-9 and CEA.
In pancreatic cancer cFN showed a lower sensitivity than CA 19-9,
55% vs 79%, but a higher sensitivity than CEA (30%) (Table 1).
Also, in detecting intra- and extrahepatic cholangiocarcinoma, CA
19-9 (89%) was superior to cFN (52%) and CEA (22%). Only one
patient with pancreatic cancer had an elevated cFN but a normal
CA 19-9 level. All cholangiocarcinoma patients with high plasma
concentrations of cFN also had an increased serum concentration
ofCA 19-9.
EDAcFN immunoreactivity was recently demonstrated in normal
livers, cirrhotic livers and in hepatocellular carcinomas (Koukoulis
et al, 1995). The carcinomas clearly showed stronger staining inten-
sity than their normal andbenign counterparts. These findings are in
concordance with our findings in plasma. Fourteen out of 21
patients with liver tumours (intrahepatic cholangiocarcinomas
excluded) showed an elevated cFN level. Cellular FN showed a
higher sensitivity for liver tumours than CA 19-9 and CEA (Table
1). On the other hand, AFP is commonly considered to be the best
marker for hepatocellular carcinomas. Serum AFP was not deter-
mined in all our patients, but in 18 patients the AFP levels were
available from clinical records. The sensitivity (AFP > 10 U 1-')
of 61% was inferior to that of cFN (72%) (data not shown). Four
AFP-negative patients had an elevated cFN level. A combination of
both markers increased the sensitivity to 83% (15 out of 18
patients). On the other hand, the cFN level was also elevated in 7
out of22 (17%) ofour patients with benign liverdiseases, who were
mostly patients with alcoholic cirrhosis. In addition, these findings
are in concordance with those from immunohistochemical studies
(Koukoulis et al, 1995). The specificity and sensitivity of the cFN
assay need to be evaluated in a much larger number ofpatients with
benign and malignant liver diseases. However, based on this small
amount of data, the concomitant use ofcFN and AFP seems a very
promising possibility ofincreasing the sensitivity for hepatocellular
carcinoma, which in many parts of the world is one of the major
forms of cancer.
The proportion ofpatients with elevated marker levels is usually
rather low in the early stages of colorectal cancer. Interestingly, in
Dukes' stage B colorectal cancer, i.e. tumours with neither local
nor distant metastases found at operation, four out ofnine patients
had an elevated cFN level, but only one patient had an abnormal
CEA level and none of the patients had an elevated CA 19-9 level
(Table 1). In higher stage groups, CEA and CA 19-9 were more
often elevated than cFN. The number of patients with colorectal
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cancer was small in this study, but the results are very encour-
aging. Samples will now be collected prospectively and cFN will
also be studied in detecting early recurrence of colorectal cancer
after resections for cure.
Cellular FN was most often elevated in patients with various
adenocarcinomas, which constituted the majority of all malignant
tumours ofthis study; but cFN was also expressed in some epithe-
lial carcinomas and sarcomas and in one melanoma of the eye,
whereas none of the patients with lymphomas had an elevated
cFN level.
One of the main disadvantages of the CA 19-9 test is the high
proportion of elevated values in patients with benign hepato-
pancreato-biliary diseases, particularly in patients with cholestasis
(Haglund et al, 1986; Steinberg et al, 1986). In some of these
patients the plasma cFN level was also elevated, but the cFN level
was often elevated in patients not showing an elevated CA 19-9
level. In benign biliary diseases, only 4 out of 59 had elevation of
both cFN and CA 19-9. Eleven had an elevated CA 19-9 level only
and one patient an elevated cFN level only. Biliary obstruction was
seen in 22 out of59 patients. Nine ofthese had an elevated CA 19-
9 level and four an elevated cFN level. Plasma cFN was elevated
in nine and CA 19-9 in 8 out of 38 patients with benign pancreatic
diseases. Only three of the patients had elevation ofboth cFN and
CA 19-9. It seems that different mechanisms cause elevation of
cFN and CA 19-9 in patients with extrahepatic cholestasis. In
benign liver diseases, six out of seven patients with abnormal cFn
also had an elevated CA 19-9 level.
In spite ofthe fact that the EDAcFN structure recognized by the
monoclonal antibody DH I represents a different type of tumour
marker than CA 19-9 and CEA, cFN was often elevated in patients
who also had an elevated CA 19-9 and/or CEA level. A small
advantage was, however, achieved by combining cFN with CA 19-
9 and CEA. Concomitant use of cFN and CA 19-9 increased the
overall sensitivity from 31% for cFN alone and 33% for CA 19-9
to 47% (Table 3). A corresponding increase from 31% and 17%,
respectively, to 41% was seen when combining cFN and CEA.
The overall accuracy, reflecting the proportion of correct benign
and malignant diagnoses out of all patients tested, was 55% for
both cFN and CA 19-9 and 43% for CEA. The accuracy increased
to 60% by combining cFN with CA 19-9 orCEA. In digestive tract
diseases, the accuracy for the combination of cFN and CA 19-9
(71%) was similar to that ofCA 19-9 alone.
This study includes only preoperative data. However, the main
clinical benefit of most markers is in follow-up of surgically
treated patients and in monitoring the response to chemotherapy
and radiotherapy. The possible use of cFN in monitoring cancer
patients will be evaluated in an ongoing study.
In conclusion, EDAcFN EIA is a new tumour marker test for
measuring the circulating levels of the extra domain A-containing
isoform ofcellular fibronectin, a component mainly found in extra-
cellular matrices. The highest frequency ofelevated values was seen
in patients with digestive tract diseases. In pancreatic and bile duct
cancers, it does not provide additional information to that obtained
using CA 19-9. The greatest advantage over CA 19-9 and CEA was
seen in patients with local colorectal cancer and in hepatocellular
carcinomas. In liver tumours the sensitivity was superior to that of
AFP, and concomitant use ofcFN and AFP raised the sensitivity to
86%. Although the total number ofpatients in this study was large,
the number of patients in many diagnosis groups was still too small
for definite conclusions to be drawn. The results however are most
encouraging and further studies have been started.
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